Pacific Biosciences of California, Inc.
PACB
$1.13
$0.043.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 154.01M | 173.15M | 188.87M | 200.43M | 200.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 154.01M | 173.15M | 188.87M | 200.43M | 200.52M |
| Cost of Revenue | 106.14M | 118.71M | 129.56M | 139.55M | 142.32M |
| Gross Profit | 47.87M | 54.43M | 59.32M | 60.88M | 58.20M |
| SG&A Expenses | 175.02M | 164.97M | 171.56M | 173.75M | 169.82M |
| Depreciation & Amortization | 27.40M | 27.40M | 21.47M | 14.81M | 8.14M |
| Other Operating Expenses | 998.00K | 3.44M | 3.44M | 3.44M | 3.44M |
| Total Operating Expenses | 444.48M | 460.62M | 494.12M | 513.23M | 510.89M |
| Operating Income | -290.46M | -287.47M | -305.25M | -312.80M | -310.37M |
| Income Before Tax | -309.54M | -394.96M | -411.81M | -308.32M | -318.16M |
| Income Tax Expenses | 316.00K | -718.00K | -11.42M | -11.42M | -11.42M |
| Earnings from Continuing Operations | -309.85 | -394.24 | -400.38 | -296.90 | -306.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -309.85M | -394.24M | -400.38M | -296.90M | -306.74M |
| EBIT | -290.46M | -287.47M | -305.25M | -312.80M | -310.37M |
| EBITDA | -249.28M | -246.15M | -271.13M | -285.97M | -290.64M |
| EPS Basic | -1.14 | -1.46 | -1.50 | -1.14 | -1.21 |
| Normalized Basic EPS | -0.65 | -0.65 | -0.70 | -0.72 | -0.73 |
| EPS Diluted | -1.14 | -1.46 | -1.50 | -1.14 | -1.22 |
| Normalized Diluted EPS | -0.64 | -0.65 | -0.70 | -0.72 | -0.73 |
| Average Basic Shares Outstanding | 1.10B | 1.08B | 1.06B | 1.04B | 1.01B |
| Average Diluted Shares Outstanding | 1.12B | 1.08B | 1.06B | 1.04B | 1.01B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |